4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Cybin D/B/A Helus Pharma (HELP) operates in the Biotechnology industry and is headquartered in Toronto, Canada with about 100 employees. Its market capitalization is roughly $415 million. In the fiscal year ended 2026-03-31, HELP reported $0M in revenue and ($148M) in net income.
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | — |
| Gross Profit | — | — | — | — | $0M |
| Operating Income (EBIT) | ($143M) | ($103M) | ($79M) | ($52M) | — |
| Net Income | ($148M) | ($82M) | ($78M) | ($48M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($48M) | ($41M) | ($29M) | ($25M) | ($33M) | — |
| Net Income | ($47M) | ($43M) | ($34M) | ($25M) | ($31M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | $251M | $180M | $302M | $54M | — |
| Total Liabilities | $19M | $15M | $10M | $6M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HELP viewer.
About TickerBase · Data methodology & sources